Bifunctional Compounds Degrade TDP-43 Aggregates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Alzheimer's disease, and Huntington's disease lack effective solutions for modulating pathological protein aggregates, particularly those involving TDP-43, which are a major component in these conditions.
Innovation Solution
Development of novel bifunctional compounds that target and facilitate the degradation of TDP-43 aggregates, including specific structures represented by formulas (I) and (II), which can be administered to prevent or alleviate symptoms associated with these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for neurodegenerative diseases, then existing therapeutic approaches are maintained, but they fail to effectively modulate pathological protein aggregates
Solution Approach 1:
The patent applies parameter changes by modifying molecular structures (formulas I and II with varying substituents R1-R6, X-Y-Z linkers) to create compounds with different binding affinities and degradation efficiencies toward pathological protein aggregates, thereby optimizing therapeutic effectiveness while maintaining the core mechanism of action
Solution Approach 2:
The patent employs composite materials by designing bifunctional compounds that combine multiple functional groups (e.g., beta-lactone warheads, hydrophobic aromatic rings, polar substituents) within a single molecular structure, enabling simultaneous engagement with multiple targets or mechanisms to enhance both reliability and adaptability in treating neurodegenerative diseases
2Reliability
If novel bifunctional compounds are developed to target TDP-43 aggregates, then degradation of misfolded proteins is facilitated, but the complexity of the treatment approach increases
Solution Approach 1:
The patent applies the extraction principle by isolating and targeting specifically the pathological protein aggregates (TDP-43, tau, huntingtin) for degradation while leaving normal cellular functions intact, achieved through selective binding of the bifunctional compounds to misfolded protein structures, thus improving reliability without requiring complex system-wide modifications
Solution Approach 2:
The patent uses intermediary compounds (formulas I and II) as mediators that bridge the gap between cellular proteolytic systems and pathological protein aggregates. These compounds act as intermediaries that facilitate recognition and degradation of misfolded proteins by cellular machinery, simplifying the overall approach compared to directly engineering complex cellular repair systems
Data Source
AI summary
Disclosed herein are compounds designed and used in the degradation of pathogenic protein aggregates and oligomers, thus these compounds are suitable for use as medicaments for preventing and/or treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), Alzheimer's disease (AD), and Huntington's disease (HD).